香港股市 已收市

Zymergen Inc. (ZY)

NasdaqGS - NasdaqGS 即時價格。貨幣為 USD。
加入追蹤清單
3.2300+0.2400 (+8.03%)
收市價: 04:00PM EDT
3.2400 +0.01 (+0.31%)
市前: 08:56AM EDT
全螢幕
交易股價資料並非來自所有市場
前收市價2.9900
開市3.1000
買盤3.3000 x 1800
賣出價3.4100 x 3000
今日波幅3.0100 - 3.2850
52 週波幅1.1000 - 14.6800
成交量1,120,728
平均成交量1,732,664
市值336.24M
Beta 值 (5 年,每月)
市盈率 (最近 12 個月)
每股盈利 (最近 12 個月)-3.6100
業績公佈日2022年5月12日
遠期股息及收益率無 (無)
除息日
1 年預測目標價2.30
  • Benzinga

    Ginkgo Bioworks Expands Horizontal Synthetic Biology Platform With This Stock Deal

    Ginkgo Bioworks Holdings Inc (NYSE: DNA) agreed to acquire Zymergen Inc (NASDAQ: ZY) in an all-stock transaction. Zymergen stockholders will receive 0.9179 shares of Ginkgo's Class A common stock for each Zymergen share. The deal values Zymergen at approximately $300 million and would provide Zymergen shareholders about 5.25% pro forma ownership of Ginkgo. Ginkgo plans to integrate Zymergen's core automation and software technologies for scaling strain engineering capacity into its foundry, incl

  • Benzinga

    Zymergen Highlights Early Results From Work On Potential COVID-19 Drug Candidate

    Zymergen Inc (NASDAQ: ZY) announced early results from its work on infectious disease, discovering several potential novel hits against malaria, tuberculosis, and COVID-19 targets. Hits for PfAPP, a critical target in the treatment of malaria, are now being advanced for validation, with hits for an emerging COVID-19 target, PLpro, expected to follow. The multi-target infectious disease program is supported by a Bill & Melinda Gates Foundation grant, enabling Zymergen to identify novel hits for a

  • Insider Monkey

    10 Best Biotech Stocks Under $20 in Cathie Wood’s Portfolio

    In this article, we discuss the 10 best biotech stocks under $20 in Cathie Wood’s portfolio. If you want to skip our detailed analysis of these stocks, go directly to 5 Best Biotech Stocks Under $20 in Cathie Wood’s Portfolio. ARK Investment Management sits on a portfolio value of nearly $42 billion as of Q3, compared […]